| |
| Proprietary Products |
| Innovative Medical Care. Improved Patient Comfort |
| Through our Proprietary Products business, we reaffirm our commitment towards our continual search towards finding solutions for unmet medical needs, affordability and patient comfort. |
|
| This segment involves the discovery of New Chemical Entities (NCEs) and differentiated formulations for subsequent commercialisation and out-licensing. It also involves our specialty pharmaceuticals business which launched sales and marketing operations for in-licensed dermatology products in the year ended March 31, 2009. |
|
| We are building world-class capabilities and forging strategic partnerships to accelerate the discovery and development of new and improved therapies to address a wider spectrum of diseases. |
|
| Our Proprietary Products business consists of the following segments: |
|
| |
|
|
| |
GENERIC BIOPHARMACEUTICALS |
|
| |
Producing innovative and affordable medicines for chronic and life threatening diseases |
|
|
|
|
| |
NEW CHEMICAL ENTITIES |
|
| |
addressing unmet medical needs |
|
|
|
|
| |
DIFFERENTIATED FORMULATIONS |
|
| |
accelerating the development of new & improved therapies for enhanced patient comfort |
|
|
| |
| Remodelling Innovation |
| As part of a major restructuring exercise this year, we moved our discovery research operations to Bangalore based Aurigene - one of our wholly-owned
subsidiary. In its place, we established a new semi-virtual research and development unit to work on developing proprietary products in collaboration with Aurigene and other discovery biotechnology companies. |
|
| We transferred most of the fixed cost discovery research resources including employees, facility and infrastructure to Aurigene, However, we continue to retain all of the Intellectual Property. The new unit focuses not only on developing new chemical entities, but also novel differentiated formulations, otherwise commonly known as repurpose medicines, optimised drugs, etc. |
|
| This restructuring has helped us move a greater portion of our research spends towards advancing projects and less on fixed overheads. The resultant cost structure is more variable. Consequently, it is accelerating our progress towards creating a self-sustaining proprietary products business. |
|
| This reorganisation also lends us the flexibility to collaborate with numerous discovery biotechnology companies, including Aurigene, to tap their expertise in niche areas of our interest. This ensures cost-effective management of our ongoing and future pharmaceutical programmes. |
|
|
|
|
|
| Post-remodelling, while our approach and mechanisms have changed, our fundamental mission of developing innovative medicines has remained constant. |
|
| Rather than creating products completely from scratch, we now work towards making existing products better. By doing so, we are only trying to be more efficient about how we utilise our resources to build, design and develop products that can truly make a difference. It is our mantra of doing more with less. |
|
| |
|
| |
Currently, we are working on multiple problems which are challenging global medical issues. These include pain, infection and metabolic disorders. |
| |
|
|
|
| Our focus on innovating medicine is not just based on meeting unmet needs but also on how our organisation is making a significant contribution in this area. We try to fill fundamental gaps. Our emphasis today lies in improving what exists and marks a shift from the previous fundamental science model of going back to the drawing board. |
|
| Today, our energy is focussed on Differentiated Formulations. And although we continue to operate in the NCE research division, it is now a much more targeted effort. |
| |
| The 3 Segments of Innovation |
 |
|
